<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Willems, Tom</style></author><author><style face="normal" font="default" size="100%">David Lefebvre</style></author><author><style face="normal" font="default" size="100%">Goris, Nesya</style></author><author><style face="normal" font="default" size="100%">Diev, Vyacheslav I</style></author><author><style face="normal" font="default" size="100%">Kremenchugskaya, Svetlana R</style></author><author><style face="normal" font="default" size="100%">Paul, Guntram</style></author><author><style face="normal" font="default" size="100%">Haas, Bernd</style></author><author><style face="normal" font="default" size="100%">Kris De Clercq</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Characteristics of serology-based vaccine potency models for foot-and-mouth disease virus.</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccine</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Vaccine</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style  face="normal" font="default" size="100%">Foot-and-Mouth Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Foot-and-Mouth Disease Virus</style></keyword><keyword><style  face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Neutralization Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style  face="normal" font="default" size="100%">Roc Curve</style></keyword><keyword><style  face="normal" font="default" size="100%">Statistics as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Vaccines</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012 Aug 31</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">30</style></volume><pages><style face="normal" font="default" size="100%">5849-55</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Foot-and-mouth disease (FMD) vaccine potency testing involves hundreds of animals each year. Despite considerable efforts during the past decades, a challenge-free alternative vaccine potency test to replace the European protective dose 50% test (PD(50)) has not been implemented yet. The aim of the present study was to further characterize the properties of serological vaccine potency models.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Logistic regression models were built for 5 serological assays from 3 different laboratories. The serum samples originated from 5 repeated PD(50) vaccine potency trials with a highly potent A/IRN/11/96 vaccine. Receiver Operating Characteristic analysis was used to determine a serological pass mark for predicting in vivo protected animals. Subsequently, an estimated PD(50) was calculated and the serotype dependency of the logistic models was investigated.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Although differences were observed between the laboratories and the serological assays used, the logistic models accurately predicted the in vivo protection status of the animals in 74-93% of the cases and the antibody pass levels corresponded to 84-97% of protection, depending on the serological assay used. For logistic models that combine different serotypes, the model fit can be increased by inclusion of a serotype factor in the logistic regression function.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;The in vitro estimated PD(50) method may be at least as precise as the in vivo PD(50) test and may accurately predict the PD(50) content of a vaccine. However, the laboratory-effect and the serotype-dependency should be further investigated.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">40</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/22824343?dopt=Abstract</style></custom1></record></records></xml>